News Articles Tagged: EGFR T790M

AZD-9291 (Osimertinib): A Breakthrough for EGFR T790M NSCLC Patients

Explore the clinical significance of AZD-9291 (Osimertinib) for EGFR T790M NSCLC, its regulatory journey, and NINGBO INNO PHARMCHEM CO.,LTD.'s role in supporting pharmaceutical manufacturing.

Navigating Resistance: The Role of Osimertinib Mesylate in Advanced NSCLC

Understand how Osimertinib Mesylate helps navigate resistance in advanced NSCLC, offering a crucial treatment pathway for patients with T790M mutations. Learn about its chemical properties.

The Science Behind Osimertinib Mesylate: Targeting T790M Mutations

Delve into the scientific mechanism of Osimertinib Mesylate, a covalent irreversible EGFR inhibitor, and its specific action against T790M mutations in NSCLC. Learn about its pharmaceutical intermediate role.

Osimertinib Mesylate: A Powerful Tool for Non-Small Cell Lung Cancer Patients with Resistance Mutations

Explore how Osimertinib Mesylate addresses resistance in NSCLC, focusing on its effectiveness against the T790M mutation and its role in subsequent treatment lines.